Dr Kelley on the Need for Additional Second-line Therapies in Cholangiocarcinoma

R. Kate (Katie) Kelley, MD, discusses unmet needs and treatment challenges within the current standard-of-care for patients with cholangiocarcinoma.

Related Keywords

California ,United States ,San Francisco ,R Kate Katie Kelley , ,Department Of Medicine ,University Of California ,Cancer Immunotherapy Program ,Clinical Medicine ,Novel Therapeutic Approaches To Target Fgfr2 Mutations In Cholangiocarcinoma ,Onclive Tv ,Publication ,